Aristotle Capital Boston LLC Has $16.43 Million Stock Position in Acadia Healthcare Company, Inc. $ACHC

Aristotle Capital Boston LLC increased its stake in Acadia Healthcare Company, Inc. (NASDAQ:ACHC) by 15.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 663,653 shares of the company’s stock after purchasing an additional 88,361 shares during the quarter. Aristotle Capital Boston LLC’s holdings in Acadia Healthcare were worth $16,432,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Abrams Bison Investments LLC lifted its stake in Acadia Healthcare by 96.7% during the second quarter. Abrams Bison Investments LLC now owns 3,580,000 shares of the company’s stock valued at $81,230,000 after buying an additional 1,760,000 shares in the last quarter. Deerfield Management Company L.P. purchased a new position in shares of Acadia Healthcare in the third quarter worth approximately $29,440,000. Rubric Capital Management LP acquired a new stake in shares of Acadia Healthcare during the third quarter valued at approximately $27,236,000. Wellington Management Group LLP lifted its position in shares of Acadia Healthcare by 11.8% in the 3rd quarter. Wellington Management Group LLP now owns 9,423,548 shares of the company’s stock valued at $233,327,000 after acquiring an additional 993,205 shares in the last quarter. Finally, Amundi boosted its stake in Acadia Healthcare by 1,006,804.5% in the 2nd quarter. Amundi now owns 896,145 shares of the company’s stock worth $20,782,000 after purchasing an additional 896,056 shares during the period.

Acadia Healthcare News Summary

Here are the key news stories impacting Acadia Healthcare this week:

• Positive Sentiment: Acadia added Daniel Cancelmi to its Board of Directors, a governance move that can be viewed positively as expanding board expertise and oversight. Article Title
• Neutral Sentiment: Reported short-interest data shows zero shares and days-to-cover of 0.0 — the release appears to contain anomalous or missing data (NaN/0) and therefore provides no clear signal about bearish positioning.
• Negative Sentiment: Zacks Research cut multiple near-term and multi-year EPS estimates and keeps a “Hold” rating. Key changes include Q2 2026 EPS cut to $0.49 (from $0.66), FY2026 to $1.48 (from $1.85), and FY2027 to $1.55 (from $1.96), plus several quarter-by-quarter reductions across 2026–2027. These downward revisions lower investor expectations and are the main reason for today’s downward pressure on the stock.

Acadia Healthcare Stock Down 2.6%

Acadia Healthcare stock opened at $23.52 on Friday. Acadia Healthcare Company, Inc. has a twelve month low of $11.43 and a twelve month high of $31.04. The company has a debt-to-equity ratio of 1.27, a quick ratio of 1.55 and a current ratio of 1.55. The firm has a market cap of $2.17 billion, a PE ratio of -1.93, a P/E/G ratio of 7.95 and a beta of 0.74. The firm’s 50 day moving average price is $16.80 and its two-hundred day moving average price is $18.76.

Acadia Healthcare (NASDAQ:ACHC) last issued its earnings results on Wednesday, February 25th. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.04. Acadia Healthcare had a negative net margin of 33.29% and a positive return on equity of 6.53%. The company had revenue of $821.46 million during the quarter, compared to analyst estimates of $800.10 million. During the same quarter last year, the business posted $0.64 EPS. The company’s revenue for the quarter was up 6.1% on a year-over-year basis. Acadia Healthcare has set its FY 2026 guidance at 1.300-1.550 EPS and its Q1 2026 guidance at 0.250-0.300 EPS. On average, research analysts predict that Acadia Healthcare Company, Inc. will post 3.38 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. Cantor Fitzgerald set a $17.00 price objective on shares of Acadia Healthcare in a research report on Wednesday, December 3rd. Zacks Research raised Acadia Healthcare from a “strong sell” rating to a “hold” rating in a research report on Thursday, March 5th. Jefferies Financial Group downgraded Acadia Healthcare to a “hold” rating in a report on Thursday, January 22nd. Raymond James Financial reissued an “outperform” rating and set a $25.00 price target on shares of Acadia Healthcare in a research report on Thursday, February 26th. Finally, Bank of America downgraded Acadia Healthcare from a “neutral” rating to an “underperform” rating and reduced their price objective for the stock from $21.50 to $13.00 in a research note on Wednesday, December 3rd. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $21.15.

About Acadia Healthcare

Acadia Healthcare Company, Inc (NASDAQ: ACHC) is a publicly traded provider of behavioral healthcare services headquartered in Franklin, Tennessee. Founded in 2005, the company has grown through organic expansion and strategic acquisitions to establish itself as a leading specialist in mental health and addiction treatment across the United States.

Acadia operates a diversified network of inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and intensive outpatient programs.